Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Celecoxib

A non-steroidal anti-inflammatory drug that selectively blocks the COX-2 enzyme, discovered in the United States by a team led by chemist John Talley and approved in 1998 for osteoarthritis and rheumatoid arthritis. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?The existence of its target, the COX-2 enzyme, had been confirmed only in 1991, when Dan Simmons of Brigham Young University cloned it: just seven years passed from enzyme to medicine.

CelecoxibGo to the active ingredient →
CelecoxibActive ingredientCelecoxibCat. No. P-C110-001CAS 169590-42-5
Celecoxib-d7Isotopically labelledCelecoxib-d7Cat. No. P-C110-005CAS 544686-21-7

EDQM standards 3

The official European Pharmacopoeia standards for this family.

Reference substanceCelecoxib CRSEDQM code Y0001445Family Celecoxib

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.